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There is increasing evidence that changes in cellular glycosylation
attend alterations in cell behaviour in both normal and in patholog-
ical processes, and that this may be of particular interest in malig-
nancy. The lectin from Helix pomatia (HPA) has emerged as an
interesting marker of altered glycosylation in cancer, where
expression of glycoconjugates recognised by the lectin appear to
be associated with poor patient prognosis (see Mitchell and
Schumacher, 1999; Brooks, 2000 for review). This association has
been reported in breast cancer (Fenlon et al, 1987; Leathem and
Brooks, 1987; Fukutomi et al, 1989, 1991; Alam et al, 1990;
Noguchi et al, 1993a, 1993b, 1994; Thomas et al, 1993), and also
in adenocarcinomas at other common sites, including gastric
cancer (Macartney, 1986; Kakeji et al, 1991; Maehara et al, 1995;
Okuyama et al, 1998), carcinoma of the oesophagus (Yoshida et al,
1993, 1994a,b) colorectal carcinoma (Ikeda et al, 1994;
Schumacher MD et al, 1994a, 1994b), carcinoma of the thyroid
(Sasano et al, 1989) and prostate cancer (Shiraishi et al, 1992).
Only one published study has failed to confirm this relationship
(Gusterson et al, 1993), and it appears that this may have been the
fault of the inappropriate methodology employed (Brooks et al,
1996). 
As a prognostic marker, HPA binding has been shown to be
independent of other established prognostic factors (including
tumour size, histological grade, tumour type, S-phase fraction,
ploidy) except for nodal status, a very physical indication that the
tumour is metastatically competent, and with which HPA binding
is very closely associated (Brooks et al, 1993). In view of the
increasing evidence of the roles of oligosaccharides in a whole
variety of cell communication and cell adhesion events, research
into the potential involvement of HPA-binding glycoforms in the
biology of the metastatic cascade is warranted. Currently, this is an
area that has been under-researched. 
HPA has a limited binding repertoire, in that, unusually for a
lectin, its combining site may be no larger than a single terminal
non-reducing  α -N-acetylgalactosamine residue (Hammarstrom
and Kabat, 1969), and it will thus recognise any glycoconjugate
terminating in this structure. Preliminary analyses have indicated
that HPA recognises a heterogeneous range of glycoconjugates in
breast cancer, including, amongst others, glycoproteins bearing the
Tn epitope (N-acetylgalactosamine-O-Ser/Thr) and blood group A
substance (Brooks et al, 1993). However, the HPA-binding part-
ners have been imprecisely characterised, and it remains unclear
whether different tumour samples express the same, or different,
profiles of HPA-binding molecules, and whether any, or all of
these are expressed by ‘normal’ cells. Perhaps more crucially,
there has been little or no research into their potential involvement
in metastatic mechanisms. 
The study described in this paper therefore has two principal
aims. Firstly, as a prelude to investigating the role(s) of HPA-
binding glycoconjugates in the processes of breast cancer metas-
tasis, we wished to characterise a range of breast cell lines (derived
from either ‘normal’ breast epithelium, primary breast carcinoma
or breast carcinoma of metastatic origin) for their expression of
HPA-binding glycoconjugates in order to establish their suitability
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approached by comparison of HPA-binding characteristics at the
cytochemical level and subsequent analysis of HPA-binding
glycoproteins with those of human clinical tumour samples and
normal breast epithelium. Secondly, and as a result of this analysis,
we wished to clarify whether different tumour and cell line
samples produce the same or different profiles of HPA-binding
glycoproteins, and whether these were unique to malignant cells,
or also produced by normal breast epithelial cells. 
MATERIALS AND METHODS 
Cell lines 
7 breast epithelial cell lines were chosen to provide a range of
phenotypic and behavioural characteristics ranging from ‘normal’
to highly tumorigenic/metastatic. Details are listed in Table 1.
Cells were cultured in Dulbecco’s Modified Eagles Medium F-12
(DMEM F-12, Gibco-BRL) supplemented with 10% heat inacti-
vated fetal calf serum (FCS) (Harlan Sera-Labs), 2 mM L-gluta-
mine (Gibco-BRL) and 50 µ gm l –1 penicillin and streptomycin
(Gibco-BRL). Adherent cell monolayers were routinely harvested
for passaging using 0.05% trypsin-0.02% EDTA (Gibco-BRL). 
Preparation of cultured cells for light microscopy 
Cells were cultured for 24 hours in the absence of FCS, monolayers
were scraped from the culture flask and washed in Tris-buffered
saline (TBS), pH 7.6, containing 0.02% w/v MgCl2, 0.01% w/v
CaCl2. As previous clinical studies on HPA binding have employed
routinely fixed and processed paraffin wax-embedded tissue, cells
were treated in a comparable manner. They were fixed overnight at
4˚C in 4% v/v formol saline, washed in TBS and resuspended in a
drop of 4% w/v low melting point agarose (Sigma). Cell/agarose
pellets were then processed to paraffin wax by conventional
protocol as employed to routinely process surgical specimens. 
Preparation of cultured cells for confocal microscopy 
Cells were grown on sterile (size 0) glass coverslips for 24 hours in
the absence of FCS to near confluence. Cells were washed briefly
in TBS, permeabilised with 0.1% v/v Triton X-100 for 10 minutes,
washed, and blocked in 2.5% w/v bovine serum albumin (BSA) in
TBS. 
Preparation of cells for flow cytometry 
Cells were incubated overnight in the absence of FCS and routinely
harvested. Cells were resuspended to 106 cells in washing medium
(TBS with 1% w/v sodium azide and 2% v/v FBS). 
Preparation of cell lysates for SDS-PAGE and HPA
lectin blotting 
Cells were lysed in NP40 lysis buffer (1% w/v NP40, 0.5% w/v
sodium deoxycholate, 0.05% SDS) containing protease inhibitors,
for 30 minutes, on ice. 
Clinical tumour samples 
19 breast carcinomas excised at The John Radcliffe Hospital,
Oxford were included in this study. 15 were infiltrating ductal
carcinomas and 4 were infiltrating lobular carcinomas. Both fresh
and routinely fixed and processed, paraffin wax-embedded
samples were available for all cases. 
Preparation of fresh tumour samples for SDS-PAGE
and blotting 
Tumour tissue was dissected from surrounding fat and macroscop-
ically normal breast tissue. Samples were homogenised in ice cold
homogenisation buffer with protease inhibitors (400 mM KCl, 2
mM EDTA, 20 mM MOPS, 10 mM MgCl, 10% v/v glycerol in
distilled water), then filtered through a 0.2 µ m filter (Acrodisc)
and dialysed overnight at 4˚C against several changes of TBS. 
Normal breast epithelial membrane – milk fat globule
membrane (MFGM) 
12 samples of MFGM from healthy, lactating female donors were
included in this study. 
HPA cytochemistry at the light microscope level 
5 µ m thick paraffin wax-embedded sections of clinical tumour
samples and cultured cells were stained for the binding of HPA by
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Table 1 Characteristics of breast and breast cancer cell lines employed in this study 
Cell line Originator Reference 
HMT 3522 Established from benign fibrocystic breast tissue.  Briand et al, 1987 
Represents normal breast epithelium. Spontaneously immortalised, 
non-transformed. Non-tumorigenic in nude mice. Cells retain polarity in culture.
BT 474 Derived from primary breast cancer. Do not readily produce tumours in  Lasfargues et al, 1978
nude mice. Cells retain polarity in culture.
MDA MB 435 Derived from a pleural effusion of infiltrating ductal cancer. Parent strain  Cailleau et al, 1974
poorly tumorigenic in nude mice.
MDA MB 468 Derived from a pleural effusion of infiltrating ductal cancer.  Filmus et al, 1985
Poorly tumorigenic in nude mice.
ZR 751 Derived from malignant ascites from primary infiltrating ductal cancer.  Engel et al, 1978
Tumorigenic in nude mice in the presence of oestrogen pellets.
MCF 7 Derived from malignant pleural effusion from primary infiltrating ductal cancer.  Soule et al, 1973
This strain is tumorigenic in nude mice.
DU 4475 Derived from cutaneous metastatic nodule of primary breast origin.  Langlois et al, 1979
Tumorigenic in nude mice. Poorly differentiated.
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the indirect method described previously by Brooks and Leathem
(1991). Specificity of binding was confirmed by incubating sections
with lectin in the presence of 0.1 M GalNAc (Sigma). For negative
control, lectin was omitted. For positive control, a case previously
known to be strongly positive for HPA binding was included. 
HPA cytochemistry for confocal microscopy 
Cells were incubated with 5 µ g ml–1 HPA-FITC conjugate (Sigma)
(with 2.5% BSA in TBS) in the dark, on ice, for 30 minutes. After
washing thoroughly in TBS, cells were fixed in a 4% (v/v)
formaldehyde solution for 15 minutes, washed, and nuclei labelled
by brief incubation with 3 µ g ml–1 propidium iodide (Sigma). They
were then mounted in citifluour mountant (Agar Scientific).
Confirmation of specificity of labelling and negative controls were
as described previously. 
HPA cytochemistry for flow cytometry 
Cells were incubated in blocking medium (TBS with 0.25% w/v
BSA) for 15 minutes at room temperature. 106 cells were
suspended in 3 µ g ml–1 HPA-FITC (Sigma) conjugate in the dark
for 30 minutes, on ice, and then washed in several changes of TBS
before fixation in 4% v/v formol saline for 2 hours at 4˚C.
Unlabelled cells were included as a control to assess levels of auto-
fluorescence and confirmation of specificity of labelling was
performed as described previously. 
Flow cytometry 
All analyses were carried out on a FACScan (Becton Dickinson). 
SDS-PAGE and lectin blotting 
Samples were subjected to chloroform/methanol precipitation
according to the method described by Wessel and Flugge
(1984). They were dissolved 1:1 in sample buffer, pH 6.8
(0.0625M Tris, 4% w/v SDS, 5% w/v dithiothreitol, 18% w/v
glycerol, 0.025% w/v bromophenol blue) and placed in a boiling
water bath for 2 minutes. 20 µ g of total protein for each of the
samples was loaded per lane. Electrophoresis was performed
under denaturing conditions using the discontinuous buffer
system described by Laemmli (1970). Separated glycoproteins
were then transferred to pure nitrocellulose membrane
(Schliecher and Schuell) using a ‘Fastblot’ semi-dry electroblot-
ting system (Biometra) using the protocol described by Towbin
et al (1979). 
Probing blots for HPA binding 
All dilutions, incubations and washes were performed using TBS
with 0.1% v/v Tween-20 (TBST) and were carried out on a rocking
platform at room temperature unless otherwise stated. Blots were
blocked in 2.5% w/v BSA (Sigma) for 30 minutes. They were
incubated in 1 µ g ml–1 biotinylated HPA (Sigma) in TBS-1% w/v
BSA overnight, then with 2 µ g ml–1 horseradish peroxidase conju-
gated avidin (Sigma) for 1.5 hours and developed using the
enhanced chemiluminescence (ECL) system (Amersham Life
Sciences), according to the manufacturer’s instructions.
Confirmation of specificity of labelling and negative controls were
as described previously. 
RESULTS 
HPA cytochemistry at the light microscope level 
Cell lines 
The cell lines displayed marked differences in HPA-binding char-
acteristics as illustrated in Figure 1 and summarised in Table 2.
HMT 3522, derived from ‘normal’ breast epithelial cells, exhibited
negligible levels of HPA binding whereas all cell lines derived
from malignant breast epithelium showed some detectable HPA
binding. Significantly, levels of expression correlated well with
known tumorigenic and metastatic capability of the cells, with
more tumorigenic/metastatic lines exhibiting higher levels of
expression of HPA-binding glycoconjugates than those derived
from primary breast cancer (BT 474) or non-malignant breast
epithelium (HMT 3522). All cell lines derived from metastatic
cancer cells exhibited marked cell surface as well as significant
cytoplasmic labelling. Omission of the lectin or incubation in the
presence of 0.1 M GalNAc completely abolished labelling. 
Clinical tumour samples 
Tumour samples showed variable levels of HPA binding. One case
was judged HPA negative (5%+/–). All others were judged HPA
positive, and staining percentage and intensity ranged from 50%
Table 2 Full summary of the HPA-binding characteristics of the cell lines using HPA cytochemistry (both at
the light and the confocal microscope level) and flow cytometry approaches. Levels of HPA labelling is
indicated by the number of + designated, where – denotes no labelling, +/– denotes negligible labelling and
++++ denotes intense labelling 
HPA cytochemistry on cultured breast cell lines 
HMT 3522 ––+/– 3 3.9 
BT 474 + – + 31 10.4 
MDA MB 435 + +/– +/– 4.89 9.5 
MDA MB 468 ++ ++ +/– 19.42 19.7 
ZR 75 1 +++ +++ ++ 73.56 51.9 
MCF 7 ++++ ++++ +++ 98.66 65.9 
DU 4475 ++++ ++++ +++ 98.34 107.1 
Cell line
Flow cytometry 
(cell surface labelling)
Cell line sections
(for light 
microscopy)
Perinuclear
labelling
Cell
surface/cytoplasmic
labelling
% cells 
+ve
Relative
intensity
Whole cells (confocal microscopy)
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++ to 100% ++++. In some cases, distinct morphologically iden-
tical sub-populations of cells negative and strongly positive for
HPA binding were apparent within the same tumour mass.
Representative examples of staining in 4 cases are illustrated in
Figure 2. Omission of the lectin or incubation in the presence of
0.1 M GalNAc completely abolished labelling. 
Clinical follow up was possible in 18 of the 19 cases. The single
HPA-negative patient remained alive and well with no sign of
recurrence. Of the 17 HPA-positive cases for whom follow up was
available, 9 remained alive and well with no sign of recurrence, 3
had suffered recurrences but were alive, and 5 were dead. Specific
details relating to the clinical follow up of the 4 cases illustrated in
Figure 2 is given in Table 3. 
HPA cytochemistry of cell lines at the confocal
microscope level 
Very low levels of punctate, diffuse cytoplasmic HPA labelling were
detectable in HMT 3522 cells. BT 474 cells exhibited some cell
surface localisation, but no intracytoplasmic labelling. All cell lines
derived from metastatic breast cancer exhibited marked and striking
intracellular localisation of HPA labelling in addition to varying
levels of cell surface labelling. Intense perinuclear localisation of
HPA labelling, possibly representative of Golgi apparatus or endo-
plasmic reticulum labelling was observed, and was particularly
marked in DU 4475 and MCF 7 cells. Results are illustrated in Figure
3 and summarised in Table 2. Omission of the lectin or incubation in
the presence of 0.1 M GalNAc completely abolished labelling. 
Analysis of cell surface HPA labelling of the cell lines
by flow cytometry 
Levels of cell surface labelling were consistent with the results of
HPA cytochemistry at light and confocal microscope levels, as
summarised in Table 2. Omission of the lectin showed very low
levels of autofluorescence and incubation in the presence of 0.1 M
GalNAc completely abolished labelling. 
SDS-PAGE and HPA lectin blotting 
Milk fat globule membrane samples 
6 HPA-binding bands were detectable in all samples; representa-
tive results are illustrated in Figure 4A. These bands were also
present in the tumour and cell line samples as is clear from
1 2
3 4
Figure 2 HPA immunoperoxidase labelling of clinical tumour samples.
Counterstain haematoxylin. Panels 1–4 illustrate representative breast cancer
samples displaying a range of HPA labelling as follows: (1) 5% (+/–); (2) 40%
(++); (3) 80% (+++); (4) 100% (++++). These are the same cases as those
analysed by HPA lectin blotting illustrated in Figure 4C. Size bar = 25 µ m 
1 2 3
4 5
7
6
Figure 1 HPA immunoperoxidase labelling of cell lines analysed at the light microscope level. Counterstain haematoxylin. Panels 1–7 as follows: (1) HMT 3522;
(2) BT 474; (3) MDA MB 435; (4) MDA MB 468; (5) ZR 75 1; (6) MCF 7; (7) DU 4475. Levels of labelling ranged from negligible (HMT 3522), weak (BT 474) to
intense (DU 4475). Size bar = 15 µ m 
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comparison of Figures 4A, B and C. Levels of expression were
very low, and bands were only detectable after extended blot
development (24 hours). 
Cell lines 
An identical range of 11 major HPA-binding glycoproteins was
present in the lysates of all 7 cell lines analysed. There were
marked quantitative differences in levels of expression, with HMT
3522 expressing the lowest levels, BT 474 expressing slightly
higher levels, and all the cell lines derived from metastatic breast
cancer expressing significantly higher levels. This is readily
observed in Figure 4B. 
The 6 bands detected in the MFGM blots were also identified in
the cell line blots. 
Breast tumour samples 
Satisfactory analysis of lysates was achieved for 16 of the 20
breast cancer samples. There was no qualitative difference in
expression of HPA binding between samples, but highly marked
quantitative differences in the levels of expression were seen.
Representative results are illustrated in Figure 4C. The samples are
the same as those illustrated in Figure 2. The sample run in track 1
was 5% (+/–) for HPA binding by lectin histochemistry, track 2
was 65% (++), track 3 was 80% (+++) and track 4 was 100%
(++++). Intensity of bands detectable on the blot corresponds well
to the lectin histochemistry results on the same samples. Again,
clinical details of these cases are summarised in Table 3. 
The 11 major bands detected in the cell line blots were also identi-
fied in the blots of glycoproteins derived from the clinical samples. 
Table 3 HPA binding characteristics and clinical data relating to cases illustrated in Figures 2 and 4(C) 
Case no. Tumour type Grade Nodal status HPA binding Follow up at 5 years 
1 Infiltrating tubular I Positive 5%+ /– (negative) Recurrence free, alive and well 
2 Infiltrating ductal I Positive 65% ++ Recurrence 1400 days post operatively. Alive 
3 Infiltrating ductal I Positive 80% +++ Died 493 days post operatively 
4 Infiltrating ductal II Unknown 100% ++++ Died 1503 days post operatively 
1
4 5
7
6
2 3
Figure 3 FITC-HPA labelling of cell lines, counterlabelled with the nuclear label propidium iodide, analysed by confocal microscopy. Panels 1–7 as follows: (1)
HMT 3522; (2) BT 474; (3) MDA MB 435; (4) MDA MB 468; (5) ZR 75 1; (6) MCF 7; (7) DU 4475. HPA labelling intensity is consistent with that observed at the light
microscope level. Localisation of labelling is as follows: HMT 3522 (panel 1) negligible levels of punctate cytoplasmic labelling; BT 474 (panel 2) low levels of cell
surface labelling only; all of the other metastatically derived cells (panels 3–7) show marked perinuclear labelling as well as varying levels of cell surface labelling.
Size bar = 15 µ m 
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DISCUSSION 
The cell lines employed in this study were chosen to represent a
range of breast epithelial sources ranging from ‘normal’ to malig-
nant and highly tumorigenic/metastatic. HPA cytochemistry at the
light microscope level revealed that the cells exhibited variable
degrees of HPA binding ranging from virtually undetectable in
cells derived from ‘normal’ breast epithelium (HMT 3522), weak
in cells derived from primary breast cancer (BT 474), to very
intense levels of expression in cells derived from metastatic breast
cancers. A range of HPA-binding patterns were also observed in
the clinical tumour samples analysed in this study, ranging from
negative to intense binding, with some samples exhibiting sub-
populations of cancer cells positive and negative for HPA binding
within a single tumour sample. This has also been a frequent
observation in other studies (for example, Leathem and Brooks,
1987; Brooks and Leathem, 1991). Cellular staining patterns
in clinical samples and cell lines were similar. DU 4475, for
example, exhibited intense cell border localisation of HPA
labelling; whereas in others, for example, MDA MB 435, localisa-
tion appeared at the light microscope level to be more diffusely
cytoplasmic. These patterns have been reported in studies on clin-
ical samples (for example, Leathem and Brooks, 1987; Brooks and
Leathem, 1991). Flow cytometry confirmed levels of cell surface
labelling with HPA consistent with light microscopy results. 
Confocal laser scanning microscopy facilitated more detailed
analysis of the distribution of HPA-binding glycoconjugates
within the cultured cells. Negligible labelling of ‘normal’ HMT
3522 cells was noted. BT 474, derived from primary breast cancer,
exhibited cell surface expression, with no evidence of polarity in
expression or any cytoplasmic labelling. All cell lines derived
from metastatic breast cancer exhibited, in addition to cell-surface
binding, striking localisation in a discrete area in the perinuclear
region of the cytoplasm, possibly corresponding to Golgi appa-
ratus or endoplasmic reticulum. These observations may be
consistent with increasing disruption in glycosylation pathways
in the Golgi apparatus/endoplasmic reticulum, or in transport
pathways, leading to a concentration of immature N-acetyl-
galactosaminylated glycoforms in these cellular compartments.
Previous ultrastructural (electron microscopy) studies of cultured
breast cell lines have failed to report HPA labelling of the Golgi
apparatus (Calafat and Jannssen, 1984; Mitchell et al, 1995), but
studies of non-malignant cells from sources other than breast have
reported HPA localisation to this organelle, consistent with its role
in glycosylation (Roth, 1984; Laitinen et al, 1990; Virtanen, 1990). 
Analysis of HPA-binding glycoproteins by SDS-PAGE and
HPA lectin blotting revealed that the cell lines all expressed appar-
ently identical profiles in terms of the 11 major glycoprotein bands
detected. Intriguingly, there was a very marked quantitative differ-
ence in levels of expression, which was readily detectable by eye.
HMT 3522, derived from ‘normal’ breast epithelium, expressed
the lowest levels; BT 474, derived from primary breast cancer,
expressed moderately low levels; whereas the cell lines derived
from metastatic breast cancer all expressed quantitatively greater
levels of HPA-binding glycoproteins, entirely consistent with the
results obtained by HPA cytochemistry at both the light and
confocal level and also by flow cytometry. 
In all cell lines, 11 major glycoprotein bands were detected by
HPA lectin blotting. These bands ranged in molecular weight from
20 to 200 kDa. Previously, Schumacher et al (1995) and Mitchell
et al (1995) reported between 4 and 7 HPA-binding bands ranging
* *
* *
* *
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kDa
116
97
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45
1234
200 *
*
*
*
* *
kDa
116
97
66
45
1234567
B
C
200
kDa
116
97
66
45
12
A
Figure 4 HPA lectin blots. All blots were probed with HPA. MW markers (kDa)
are indicated to the left of the lanes. 20 µ g total protein loaded per lane. (A)
MFGM samples. Identical profiles were observed in all samples analysed and
2 representative tracks are illustrated here. In all samples analysed, 6 weak
HPA binding bands were detectable after extended development (yielding high
background). (B) Cell line lysates. Lanes 1–7 as follows: (1) HMT 3522; (2) BT
474; (3) MDA MB 435; (4) MDA MB 468; (5) ZR 75 1; (6) MCF 7; (7) DU 4475.
Levels of expression of the HPA-binding bands are quantitatively different with
HMT 3522 showing the lowest levels of expression and DU 4475 showing the
highest. Qualitatively the banding pattern is comparable, with 11 shared major
HPA binding bands * apparent. Of these, 6 appeared to correspond to those
detectable in the MFGM samples **. (C) Clinical tumour samples. Samples are
the same as in Figure 2. The levels of expression of the HPA-binding bands
are quantitively different with sample 1 showing the lowest levels and sample 4
the highest, consistent with the cytochemistry results. The 11 bands detectable
in the cell line samples* were also apparent in all the tumour samples, and
extra bands*** were also detected.  marked;  *
marked; marked 
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in molecular weight from 20–90 kDa. Including a band at 69 kDa,
which the authors tentatively identified as an N-acetylgalactos-
aminylated form of albumin, and a band at 90 kDa, tentatively
identified as the transferrin receptor. 
The analysis of lysates of primary breast cancers reported here
revealed a complex and heterogeneous array of 13 major HPA-
binding bands. Levels of expression differed markedly between
tumours, but qualitatively the profile of HPA-binding moieties
appeared entirely consistent between samples, and the 11 major
bands detected on the cell line blots were readily apparent on the
blots of the clinical samples. As in the cell line analysis, we report
a more complex profile to that reported in earlier studies, and
report expression of a similar range of HPA-binding species in
different samples. Previous analyses of primary breast cancer, and
metastases to lung, bone and liver have revealed an array of less
than 10 HPA-binding bands, quantitatively different between
samples, but as in the study reported here, with marked qualitative
similarities in the bands expressed (Brooks and Leathem, 1995;
Streets et al, 1996). The methodology employed in the current
study, using enhanced chemiluminescence (ECL), facilitates a
much greater level of sensitivity than that obtained by the peroxi-
dase/diaminobenzidine method employed in earlier studies by
ourselves (Brooks and Leathem, 1995; Streets et al, 1996) and
others (Mitchell et al, 1995) and this may account for the greater
number of HPA-binding glycoprotein moieties detected in this
study in analyses of both cell lines and clinical samples. 
Clearly, in a study of only 20 cases with a maximum of 5 years
follow up, only limited conclusions can be drawn regarding the
clinical significance of quantitative differences in expression of
HPA binding glycoproteins. However, it is noteworthy that the
single case judged to be HPA negative – panel 1 in Figure 2 and
track 1 in Figure 4(C) – remained alive and well with no sign of
recurrence, in spite of being node positive at the time of diagnosis,
while the 3 HPA-positive cases for which detailed analysis is
presented – panels 2 (65% ++), 3 (80% +++) and 4 (100% ++++)
in Figure 2 and tracks 2, 3 and 4 respectively in Figure 4(C) – had
suffered recurrences and/or died. Of the remaining 14 HPA-positive
cases in the study for whom we had follow up information, 5 had
suffered recurrences and/or died while 9 remained alive and well
at 5 years. We have previously determined (unpublished observa-
tions) that there is no prognostic significance associated with
increasing levels of HPA positivity of cases as determined by
lectin histochemistry. Tumours tend to be either completely or
almost completely negative for HPA binding, which is indicative
of favourable prognosis, or, exhibit substantial sub-populations of
cells positive for HPA binding, which is indicative of poor prog-
nosis. This is true of the 20 cases examined in this study. We might
speculate that if the HPA-binding glycoproteins play a functional
role in metastasis, their expression by a significant sub-population
of cancer cells is sufficient for dissemination to occur successfully,
and expression by a larger proportion of tumour cells will have no
additional clinical significance. 
In the current study, we detected 6 HPA-binding glycoprotein
bands in MFGM, consistent with previous reports (Streets et al,
1996). Levels of expression were extremely low in comparison to
the clinical samples and cultured cells. Normal breast epithelium
expresses some HPA-binding glycoproteins, as cytochemistry
reveals discrete luminal surface labelling of breast ducts (Leathem
and Brooks, 1987; Brooks and Leathem, 1991; Mitchell and
Schumacher, 1999; Brooks, 2000). The very limited profile of
HPA-binding glycoproteins, and very low levels of expression, by
MFGM in comparison to breast cancers or breast cancer cell lines
is consistent with a fundamental disruption in glycan processing
and/or transport with transformation and tumour progression. 
In previous studies, there has remained some ambiguity in inter-
pretation of the analysis of HPA-binding glycoproteins by breast
cancers and breast cell lines. A heterogeneous expression of HPA-
binding glycoproteins has been apparent, but it has remained
unclear whether the same, or different, HPA-binding glycoproteins
are expressed by different samples. In this study, for the first time,
we have addressed this issue directly. Results indicate that
although both cell lines and human tumours express a highly
complex array of HPA-binding moieties, and levels of expression
differ quite markedly between samples, the actual profile of glyco-
proteins is entirely consistent. It remains to isolate and characterise
these molecules further. 
In view of the relationship between positive HPA labelling and
metastatic competence in human breast cancer, there is clearly a
need to understand the potential role(s) of these glycoconjugates in
the metastatic process. From what is known about carbohydrate-
receptor (lectin) interactions in many normal and disease-associ-
ated cellular processes, it appears plausible that the HPA-binding
oligosaccharides might be ligands for a putative receptor (lectin)
on another cell type, and thus implicated in cell–cell adhesion. An
interesting paradigm is the interaction of selectins (P-selectin, L-
selectin and E-selectin) with carbohydrate-binding partners during
the complex mechanisms associated with leukocyte trafficking
(e.g. see Zak et al, 2000), and, indeed, their possible involvement
in metastasis (e.g. see Laidler and Litynska, 1997). Alternatively,
the alteration in cellular glycosylation represented by the expres-
sion of HPA-binding ligands may conversely result in a failure of
recognition by putative oligosaccharide receptors resulting in loss
of cell–cell adhesion, which could potentially be of significance in
cancer cell migration at either the primary or secondary site. It has
also been suggested (Fenlon et al, 1987) that exposure of terminal
GalNAc, detectable by HPA, might result from a failure of sialyl-
ation mechanisms, sialic acid being a common terminal mono-
saccharide which could be masking sub-terminal GalNAc in
HPA-negative tumours. As sialic acid carries a negative charge,
such disruption in sialylation would have profound effects on the
properties of the cell surface, again affecting processes such as
cell–cell adhesion. We have, however, investigated the relation-
ship between expression of GalNAc, detectable by HPA, and
expression of sialylated glycans (Brooks and Carter, 2001), and
found no evidence to support a relationship between HPA posi-
tivity and failure in sialylation. 
With the explosion of interest in glycobiology, and our
increasing understanding of the importance of carbohydrate-
receptor interactions in a whole range of biological process,
including metastasis, the potential role of altered expression
of N-acetylgalactosaminylated glycoproteins in breast – and
other – common neoplasms warrants further study. Experiments
are underway in our laboratory and early results, intriguingly,
are consistent with a function in cancer cell adhesion mecha-
nisms.  Further work is required, and there remains a need to
clarify the biological roles of these moieties in metastatic mech-
anisms, particularly in relation to cell adhesion. Only by a better
understanding of the molecular complexities of the metastatic
cascade can we hope to develop effective therapies to combat its
effects. 
The current study has demonstrated that the expression of HPA-
binding glycoproteins by a range of cell lines is consistent with
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that observed in human tumours. Levels of expression appear to be
associated with the origin of the cell types; negligible levels of
expression in cells derived from ‘normal’ breast epithelium, low
levels in cells derived from primary breast cancer, and high levels
in cells derived from metastatically competent tumours.
Furthermore, the cell lines display profiles of HPA-binding glyco-
proteins present in clinical samples. It appears, from the investiga-
tions reported here, that, taking into consideration the usual
caveats regarding cell line research, that the cell lines investigated
in this study may be appropriate tools for initial investigations.
Moreover, this study illustrates for the first time that breast cancer
cells and tissues express HPA-binding glycoproteins not detected
in normal breast epithelial membranes. Furthermore, different
samples and different cancer cell lines express quantitatively very
different levels of HPA-binding glycoconjugates, but qualitatively
very similar profiles of HPA-binding species. 
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